Cipla has launched adult Hepatitis B vaccine in India. Under a co-exclusive agreement with Serum Institute of India (SII), the company will market the vaccine for adults while SII will market it for adults and children. The agreement will enable the company to provide affordable vaccines for a chronic disease like Hepatitis B. The company’s strong marketing network and reach will ensure maximum accessibility of the vaccines in India.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.